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INTRODUCTION 
 Epidural blockade is one of the most useful and versatile procedure in 
modern anesthesiology. It is unique in that in can be placed virtually at any 
level of spinal spine, allowing more flexibility in clinical practice. It is more 
versatile than spinal anesthesia, giving the anesthetist the opportunity for 
providing continuous surgical analgesia and anesthesia. It can also be utilized 
for post operative pain control and more rapid recovery from surgery. 
 Epidural anesthesia can reduce the adverse physiologic responses to 
surgery such as autonomic hyperactivity, cardiovascular stress, increased 
metabolic rate, pulmonary dysfunction and immune system dysfunction. 
Epidural anesthesia also reduces the incidence of hyper coaguability, deep vein 
thrombosis (DVT), pulmonary embolism (PE) and also decreases 
intraoperative blood loss. Epidural anesthesia reduces venous blood pressure 
(measured in the operative wound), and this is the significant factor in 
determining surgical bleeding. 
Orthopedic anesthesia is a challenge for every anesthetist and most of 
the procedures are well suited for regional anesthetic techniques. Postoperative 
pain management, a significant problem after orthopedic procedures; with 
regional anesthetic techniques, leads to superior pain relief. In addition, severe 
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acute pain after orthopedic surgery can develop into a chronic pain syndrome, 
which may be ameliorated by aggressive perioperative analgesia. Regional 
anesthesia avoids manipulation of the airway, and conscious patients can aid in 
the safest and most comfortable positioning for surgery. The special advantage 
of epidural adjuvant was the synergistic effect that they exhibit with local 
anesthetics, which allowed a marked decrease in the dose of both drugs to 
achieve the same level of analgesia. 
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AIM OF STUDY 
 
The aim of this study is to evaluate and compare the clinical effects of 
added dexmedetomidine to epidural ropivacaine 0.75% for lower limb 
orthopedic procedures.  
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EPIDURAL ANESTHESIA 
HISTORY: 
 In 1885 Leonard Corning first performed epidural anesthesia with 
cocaine for relief of pain in an extremity. But it was apparently accidental. 
 Two French physicians, Jean-Anthanase Sicard and Ferdinand Cathelin 
have been credited with the intentional administration of caudal epidural 
anesthesia in 1901. They found that injecting a dilute solution of cocaine 
through sacral hiatus can provide effective treatment for sciatic pain and 
suggested the technique for surgical procedures.  
In 1921, Fidel Pages (1886-1923), a Spanish military surgeon, devised a 
technique to introduce epidural procaine at all levels of the neuraxis. His 
method was to use a blunt needle and then feel and hear entry of the needle 
through the ligamentum flavum.  
Achille Mario Dogliotti (1897-1966) described epidural injections of 
local anesthetics in 1931, apparently without previous knowledge of the work 
of Pages. Dogliotti performed extensive studies to determine the spread of 
solutions within the epidural and paravertebral space after injection. An 
important innovation was Dogliotti's method of identification of the epidural 
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space, with the use of continuous pressure on the plunger of a saline-filled 
syringe as the needle is advanced through the ligamentous structures and 
sudden loss of resistance when epidural space is entered. 
Gutierrez of Argentina developed the “hanging drop” sign, which is still 
used to identify the epidural space.  
In 1936 Charles B. Odom of New Orleans introduced the concept of a 
test dose to detect intrathecal injection in lumbar epidural anesthesia.  
Edward B. Tuohy (1908-1959) used a ureteral catheter threaded through 
a large Huber-tipped spinal needle to provide continuous spinal anesthesia.  
In 1947, Manuel Martinez Curbelo of Havana, Cuba, used the Tuohy 
needle and a small ureteral catheter to provide continuous lumbar epidural 
analgesia.  
Philip R. Bromage and John J. Bonica performed several studies on 
epidural dose-response relationships and the hemodynamic changes that 
followed initiation of the block.  
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Combining spinal with epidural anesthesia (CSE) began shortly after 
epidural anesthesia was reintroduced by Dogliotti.  
In 1939, Dr. A. L. Soresi presented a paper in which he and his 
colleagues provided a combination of spinal and epidural anesthesia safely to 
over 200 patients. 
In 1979, a Swedish physician named Curelaru was the first to describe a 
combined technique using separate intervertebral injections. 
Then in 1982, Coates from England and Mumtaz from Sweden 
published reports of the popular needle-through-needle approach. 
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DEFINITION 
A regional anesthesia may be considered as a reversible form of 
anesthesia of an anatomic part produced by the application of a chemical 
capable of blocking conduction in nerve tissue associated with that part without 
damaging the tissue permanently.  
Epidural anesthesia (peridural or extradural) is anesthesia obtained by 
blocking spinal nerves in the epidural space as the nerves emerge from the dura 
and then pass into the intervertebral foramina. 
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ANATOMY: 
EPIDURAL SPACE: 
 
  
 
 
 
 
 
 
The epidural space is smaller than the subarachnoid space, extends from 
foramen magnum to the sacral hiatus, and surrounds the dura mater anteriorly, 
laterally, and posteriorly .At the level of foramen magnum, the periosteal layer 
of the spinal vertebral canal fuses with the dural layers of the skull. The lower 
limit is the sacrococcygeal membrane. The epidural space is bounded 
anteriorly by the posterior longitudinal ligaments, laterally by the pedicles and 
intervertebral foramina, and posteriorly by the ligamentum flavum. Contents of 
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the epidural space include the nerve roots that traverse it from foramina to 
peripheral locations, as well as fat, areolar tissue, lymphatics, and blood 
vessels, including the well-organized Batson venous plexus. The volume of fat 
is greater in obese individuals and less in elderly, which explains the age 
related changes in epidural dose requirements.  
  Batson’s venous plexus is continuous with the iliac vessels in the pelvis 
and the azygos system in the abdominal and thoracic body walls and has no 
valves. Off-midline needle insertion more commonly result in blood vessel 
puncture due to engorged epidural veins converging into the intervertebral 
foramina.  
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To reach the epidural space in a midline sagittal plane, skin and 
subcutaneous tissues, supraspinous ligaments, interspinous ligaments and 
ligamentum flavum are penetrated. Vertebral column provides anatomic factors 
important in inserting the epidural needle, in cervical and lumbar areas the 
spinal processes are more horizontal while in the thoracic region they are 
oblique. The existence of a dorsomedian connection between the dura and the 
ligamentum flavum is of help in explaining some of the results occurring 
during the performing of clinical epidural anesthesia.  
Surface Anatomy, Structures Superficial to the Epidural Space: 
             The safest point of entry into the epidural space is below the level of 
the spinal cord. In adults, this corresponds to the lower border of the L1 
vertebrae, and in children, at the lower border of the L3 vertebrae. Epidural 
insertion in adults is commonly introduced at either the L3-4 interspinous 
space or one higher, L2-3. A line drawn between the superior aspect of the iliac 
crests crosses either the spinous process of L4 or the L4-5 interspace. The 
interspinous space above this point (L3-4 interspinous space) or one higher 
(L2-3) can safely be chosen for needle entry into the epidural space of adults.  
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Distance from Skin to Epidural Space: 
              The epidural space width is 5-6mm in the lumbar region and the 
thickness of the dura is 0.66-0.33mm. The distance from skin to epidural space 
is 4cm for 50% of patients and 4 to 6cm for 80% of patients. Maximum depth 
occurs in between L3 & L4 spines, probably related to lumbar lordosis.  
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VERTEBRAL COLUMN: 
GENERAL APPEARANCE 
The vertebral column consists of 7 cervical, 12 thoracic, and 5 lumbar 
vertebrae. At the caudal end, the 5 sacral vertebrae are fused to form the 
sacrum, and the 4 coccygeal vertebrae are fused to form the coccyx . The 
primary functions of the vertebral column are to maintain erect posture, to 
encase and protect the spinal cord, and to provide attachment sites for the 
muscles responsible for movements of the head and trunk. 
STRUCTURE OF VERTEBRAE 
Each vertebra is composed of a vertebral body and a bony arch. The arch 
consists of two anterior pedicles and two posterior laminae. The transverse 
processes are located at the junction of the pedicles and lamina, and the spinous 
process is located at the junction of the laminae. The spinous processes vary in 
their angulation in the cervical, thoracic, and lumbar regions. The spinous 
processes are almost horizontal in the cervical, lower thoracic, and lumbar 
regions, but become significantly more sharply angled in the midthoracic 
region. The greatest degree of angulation is found between the T3 and T7 
vertebrae, making insertion of an epidural needle in the midline more difficult. 
     19 
   
 
JOINTS OF THE VERTEBRAL COLUMN 
The vertebrae articulate at the intervertebral and facet joints. The 
intervertebral joints are located between adjacent vertebral bodies. They 
maintain the strength of attachment between vertebrae. The facet joints form 
between articular processes. The facet joints are heavily innervated by the 
medial branch of the dorsal ramus of the spinal nerves. This innervation serves 
to direct contraction of muscle that moves the vertebral column. 
LIGAMENTS 
The vertebrae are joined together by a series of ligaments and disks. 
Anteriorly, the vertebral bodies are separated by the intervertebral disks. The 
ligament connecting them runs from the base of the skull to the sacrum and is 
called the anterior longitudinal ligament. The posterior surface of the vertebral 
bodies is connected by the posterior longitudinal ligament, which also forms 
the anterior wall of the vertebral canal. The other ligaments of importance: 
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• Intertransverse ligaments: connects transverse processes 
• Supraspinous ligaments: attaches to the apices of the spinous processes, 
extends from sacrum to skull where it becomes the ligamentum nuchae   
• Interspinous ligaments: connects spinous processes 
• Ligamentum flavum: thick, elastic ligament, connects the laminae, 
composed of a right and left ligament that joins in the middle forming an 
acute angle; narrows toward the articular processes 
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SPINAL CORD/SPINAL CANAL 
The spinal canal is formed by adjacent vertebral foramina. The canal 
provides support and protection to the spinal cord and its nerve roots. The 
spinal cord extends from the foramen magnum to the L1-2 vertebral level in 
adults, and L3 vertebral level in children before becoming the conus 
medullaris.  
From the spinal cord extends a series of dorsal and ventral roots that 
converge to form mixed spinal nerves. The mixed nerves contains motor, 
sensory, and in many cases, autonomic fibers. There are eight cervical, 12 
thoracic, 5 lumbar, 5 sacral, and 1 coccygeal pairs of spinal nerves. The roots 
inferior to the conus medullaris become the cauda equina before exiting 
through the lumbar and sacral foramina. After the spinal nerves leave the spinal 
canal through the intervertebral foramina, they divide into the anterior and 
posterior primary rami. The posterior primary rami innervate the skin and 
muscles of the back. The anterior rami supply the rest of the trunk and the 
limbs. Each spinal nerve supplies a specific region of skin referred to as a 
dermatome. 
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Preganglionic fibers of the sympathetic nervous system originate from 
the spinal cord from T1 to L2. They travel with spinal nerves to form the 
sympathetic chain. This chain extends the entire length of the spinal column on 
the anterolateral aspects of the vertebral bodies. The chain gives rise to the 
stellate ganglion, splanchnic nerves, and the celiac plexus. 
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MENINGES/MENINGEAL SPACES 
Surrounding the spinal cord and its roots are three layers of membranes. The 
innermost layer is called the pia mater, which attaches intimately to the surface 
of the spinal cord and roots of the spinal nerves. As the roots of the spinal 
nerves extend distally, the pia mater transforms into the second layer called the 
arachnoid. The arachnoid detaches from the roots and reflects back across the 
pia, enclosing the spinal cord within a cavity called the subarachnoid space. 
The space is filled with cerebrospinal fluid and transmits blood vessels to and 
from the spinal cord. Superficial to the arachnoid is the thick dura mater. The 
space between the arachnoid and dura is called the subdural space. Because the 
arachnoid is pushed against the dura mater by the pressure of the CSF, the 
subdural space is negligible. It contains a small amount of serous fluid which 
allows the dura and arachnoid to move over each other.
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EPIDURAL PHYSIOLOGIC CONSIDERATIONS 
A negative epidural pressure was described in 1928 by Heldt and 
Moloney.In lower lumbar region it amounts to 0.5cmH2O, in upper lumbar 
region 1cmH2O and 2cmH2O in thoracic region. 
1. Cone theory: The needle introduced into the epidural space depresses the 
dura, creating a large epidural space an artifact caused by indentation of 
dura by advancing needle which creates negative pressure. 
2. Transmission theory: Negative pressure in the epidural space is caused 
by transmission of intrapleural negative pressure through the 
intervertebral foramina to epidural space. 
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SITE OF ACTION 
The site of action of local anesthetic agents in epidural include 
1. On the nerves as they traverse the epidural space. 
2. On the nerves as they pass out through intervertebral foramina,where 
spinal nerves lose their protective dural sheaths. 
3. On the nerves in the subarachnoid space-the agent having reached this 
area by diffusion through the dura. 
FATE OF EPIDURAL AGENTS (VASCULAR ABSORBTION 
PHARMACOKINETIC): 
Bromage has summarized the fate of epidural local anesthetic agents 
1. Leakage by vascular absorbtion 
2. Leakage through interverbral foramina 
3. Diffusion through dural root sleeves 
4. Diffusion through dura mater into CSF 
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FACTORS DETERMINING SPREAD OF EPIDURAL ANESTHESIA: 
1. Volume of anesthetic solution-The dose of local anesthetics necessary 
for analgesia or anesthesia is a function of the concentration of the 
solution and the volume injected. Volume is the variable that affects the 
degree of distribution of the block. Guideline for dosing an epidural in 
adults is 1–2 mL per segment to be blocked. 
2. Age factor-Spread increases with age due to the fact that escape from 
epidural space is less due to intervertebral foramina being more fixed 
and epidural vessels less penetrable. Decrease in epidural space adipose 
tissue with age may dominate the age-related changes in epidural dose 
requirements. 
3. Height factor-segment volume should be modified according to patient 
height. Up to 150cm 1.0ml/segment and increase 0.1ml/segment 
anesthetic solution for each 5cm as suggested by Bromage 
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4. Selection of interspace-Next to volume of anesthetic solution, selection 
of interspace is the single most important factor in assuring adequate 
analgesia. The epidural blockade is most effective when the block or the 
catheter is inserted in a location that corresponds to the dermatomes 
covered by the surgical incision. The most rapid onset and the densest 
block occur at the site of injection. 
DETECTION OF EPIDURAL SPACE: 
1. Hanging drop sign(Gutierrez sign)-A small drop of sterile water is 
placed at the hub of needle,when the needle advanced through the 
ligamentum flavum this drop is sucked into the epidural space. 
2. Loss of resistance technique-sudden loss of pressure exerted on the 
plunger of a syringe filled with air,saline or water as the needle advanced 
through the ligamentum flavum was used to identify epidural space. 
3. whoosh test- The “Whoosh” test involves injecting air through the 
needle while an assistant simultaneously listen with a stethoscope over 
the thoracolumbar spine in the midline. If injection of air is heard with 
the stethoscope (a positive whoosh test) then the needle was deemed to 
be correctly located in the epidural space. Saline is used instead of air in 
modified“Swoosh” test. 
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4. Lund sign-As the epidural space is entered , there is a sudden loss of 
resistance and saline is injected into the epidural space and the patient 
may experience burning pain. 
5. Bonniot’s phenomenon-On entering epidural space with a bare needle,an 
audible hiss may be noticed,signifying that air is sucked into epidural 
space. 
6. Mostert reported a reverse phenomenon.when a syringe filled with equal 
parts of air and saline is injected into epidural space ,the syringe is 
quickly reversed, there will occur an outward reflux of froth. 
7. Bidigital pressure test(BiP Test): BiP Test is that when pressure is 
applied to the tissues ,this compresses them, increasing their density and 
thus increasing resistance to the needle. 
8. Free dripping saline: The infusion set was prepared with saline and 
connected to the hub of an epidural needle. Free dripping of saline was 
regarded as a sign that the needle tip had entered the epidural space. 
9. Queckenstedt-test- new method to confirm epidural puncture by 
assessing indirect changes in epidural pressure using the Queckenstedt-
test procedure, which increases subarachnoid pressure by compressing 
the internal jugular veins . 
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CLINICAL CONSIDERATION OF EPIDURAL:        
 
 
 
 
 
 
 
 
INDICATIONS CONTRAINDICATIONS 
Poor risk patients Severe hemorrhage or shock 
Cardiac disease 
Uncooperative or apprehensive 
patients 
Pulmonary disease Previous laminectomy 
Metabolic disturbances 
Coagulation defects: patients on 
anticoagulants or hemophiliacs 
When spinal anesthesia is 
contraindicated 
Local inflammation 
When general anesthesia is 
contraindicated 
Increased intracranial pressure 
Obstetric anesthesia Allergy to local anesthetics 
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ADVANTAGES DISADVANTAGES 
The area of anesthesia is well defined Technical difficulty resulting from the 
need for accurate placement of needle. 
The duration of anesthesia is longer 
than spinal  
Incomplete muscle relaxation. 
The more severe disturbances of 
spinal naesthesia (headaches, 
meningitis, arachnoiditis) are 
minimized. 
Need for large volumes of fluid and 
hence large quantities of drug to 
achieve anesthesia . 
GI complaints are minimal. Nausea 
and vomiting are minimal. 
Danger of entering subarachnoid 
space. 
Catheterization incidence is small; 
urinary retention average 1.5%. 
Bleeding in epidural space by catheter 
injuring venous plexus 
 Spotty segmental block not infrequent 
 Occasional back pain. 
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EPIDURAL ADJUVANTS: 
Many classes of drugs have been used in epidural as adjuvants, which includes 
opioids, α-adrenergic agonists, anticholinesterases, ketamine and midazolam. 
α-adrenergic agonists used in neuraxial anesthesia along with local anesthetics 
has many advantages which includes, 
1. Prolongs and intensifies the effects of epidural local anesthetics 
without increasing the degree of hypotension for epidural 
anesthesia and analgesia 
2. Produces analgesia without motor impairment and prolongs the 
duration of the local anesthetic analgesic effect 
3. Modulates the immune stress response to surgery 
4. May reduce cytokine response, therefore further reducing pain 
sensitivity 
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PHYSIOLOGIC EFFECTS OF EPIDURAL BLOCKADE 
The primary site of action of local anesthetic solutions injected into the 
epidural space is the spinal nerve roots. The segmental nerve roots in the 
thoracic and lumbar regions are mixed nerves, containing somatic sensory, 
motor, and autonomic nerve fibers. Sensory blockade interrupts the 
transmission of both somatic and visceral painful stimuli, whereas motor 
blockade provides muscle relaxation with a varying degree of sympathetic 
blockade. The injection site for epidural anesthesia should be close to the nerve 
roots of interest in order to obtain the best results with minimal amount of local 
anesthetic and decreased risk of side effects from systemic absorption of the 
local anesthetic. 
Differential nerve block, an important concept for epidural anesthesia, 
refers to the phenomenon in which nerve fibers with different functions 
demonstrate a varying sensitivity to the effects of local anesthetics. 
Sympathetic fibers are usually blocked first followed by pain/temperature, then 
proprioception, followed by motor blockade. After an epidural block, 
sympathetic blockade (temperature) may vary from zero to four segments 
higher than the sensory block level (pain/light touch), which is two segments 
higher than motor blockade. Regression of the block occurs in reverse order. 
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The physiologic effects of epidural blockade on organ systems depends 
on the spinal level and the number of spinal segments blocked. In general, high 
thoracic epidural blocks and extensive epidural blocks are associated with more 
profound sympathetic block, resulting in a more profound physiologic effect in 
the cardiovascular system. 
CARDIOVASCULAR SYSTEM: 
BLOCK BELOW T4  
The effect of epidural anesthesia on the cardiovascular system depends 
on the level and the degree of sympathetic blockade. The sympathectomy that 
accompanies the techniques depends on the height of the block, with the 
sympathectomy typically described as extending for two to six dermatomes 
above the sensory level with spinal anesthesia and at the same level with 
epidural anesthesia. Vasomotor tone is maintained by sympathetic fibers from 
T5 to L1 that innervate vascular smooth muscle. Blockade of these fibers cause 
venodilation with venous pooling as well as arterial vasodilation with 
decreased systemic vascular resistance. The venous pooling leads to a marked 
decrease in venous return, right atrial pressure, and subsequently, cardiac 
output. The decrease in venous return can then lead to an increase in cardiac 
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vagal tone,especially for blocks near the T5 level. Clinically, the patient can be 
hypotensive withouta change or a decrease in heart rate. 
The compensatory mechanism for the decrease in mean arterial pressure 
is a reflex increase in vasoconstriction above the level of the block as well as a 
release in catecholamines from the adrenal medulla.  
BLOCK ABOVE T4 
The cardiovascular effects of a block above T4 are the result of a high 
sympathetic block. The cardiac sympathetic fibers arise from T1 to T4, and 
when blocked, profound hypotension (the result of a decrease in cardiac 
contractility) and bradycardia can occur. In addition to the cardiac effects, a 
high level of sympathetic blockade causes: 
• Increased central venous pressure without an increase in stroke 
volume 
• Vasoconstriction in the head, neck, and upper limbs 
• Splanchnic nerve blockade with blockade of medullary secretion 
of catecholamines 
• Blockade of vasoconstrictive effect on the capacitance vessels of 
the lower limbs 
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RESPIRATORY SYSTEM: 
Lung volumes (tidal volume, vital capacity), resting minute ventilation, 
and dead space are basically unchanged even with a higher thoracic epidural. 
Even with abdominal or intercostal muscle paralysis by a high thoracic block, 
major alteration in pulmonary function is not seen. 
There is concern regarding the use of epidural blockade in patients with 
severe chronic lung disease patients dependent on accessory muscle function to 
maintain adequate ventilation, because paralysis of respiratory muscles and 
changes in bronchial tone from epidural analgesia can occur. Thoracic epidural 
analgesia with 0.25% bupivacaine did not adversely affect ventilator 
mechanics, breathing pattern, gas exchange, and inspiratory muscle force 
generation even in COPD patients.Respiratory arrest in epidural blockade is 
from the sympathetic block, leading to decreased cardiac output with 
subsequent reduced blood flow to the brain. 
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GASTROINTESTINAL SYSTEM: 
The gastrointestinal effects of epidural anesthesia are largely the result 
of blockade of the sympathetic splanchnic fibers from the T5 through L1 level. 
Unopposed vagal dominance leads to an increase in secretions; peristalsis; and 
a small, contracted gut. Postoperatively, gastrointestinal motility returns more 
quickly when epidural analgesia with a local anesthetic is instituted. Segmental 
sympatholysis creating an increase of sympathetic activity in segments below 
the block leads to impaired splanchnic blood flow. Nausea is a related to 
increased gastric peristalsis secondary to unopposed vagal activity. It can be 
prevented by promptly treating hypotension with a fluid bolus, ephedrine. 
Atropine has been shown to be an effective treatment for nausea associated 
with a high thoracic block. 
RENAL/GENITOURINARY SYSTEM: 
Since renal blood flow is maintained through autoregulation, an epidural 
has very little effect on renal function. Neuraxial blockade at the lumbar level 
has been postulated to impair control of bladder function secondarily to 
blockage of the S2 to S4 segments. Urinary retention may occur until the block 
wears off.  If a continuous epidural is used, then urinary catheterization may be 
necessary.  
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NEUROENDOCRINE SYSTEM: 
 Increased protein catabolism and oxygen consumption are common. 
Increased plasma concentrations of catecholamines, vasopressin, growth 
hormone, renin, angiotensin, cortisol, glucose, antidiuretic hormone, and 
thyroid-stimulating hormone have been documented and referred to as the 
surgical stress response. Intraoperative manifestations of the response is 
demonstrated as hypertension, tachycardia, hyperglycemia, suppressed immune 
function, and altered renal function. Afferent sensory information from the 
surgical site is thought to play a pivotal role in the response.The response can 
be completely abolished by an appropriate level of sensory blockade produced 
by regional anesthesia. The inhibitory effect is greatest with lower abdominal 
and lower extremity surgery and slightly less effective in upper abdominal and 
thoracic surgery, probably because the epidural cannot completely block all 
nociceptive afferent pathways. 
The most critical effect of neuroendocrine activation in the perioperative 
period is the increase in plasma norepinephrine, which peaks about 18 h after 
the surgical stimulus is initiated. The increase in plasma norepinephrine is 
associated with activation of nitric oxide in the endothelium of patients with 
atherosclerotic disease, producing paradoxic vasospasm. Thus, in patients with 
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significant atherosclerotic disease, the combination of paradoxic vasospasm 
and the hypercoagulable state may be the reason underlying the 
cardioprotective effects of thoracic epidural anesthesia and analgesia in 
patients with cardiac disease. 
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PHARMACOLOGY OF EPIDURAL BLOCKADE 
The principal site of action of local anesthetics after epidural injection is 
thought to be the spinal nerve roots, the spinal cord, and possibly the brain. 
Nerve fibers with different features and function display varying sensitivity to 
local anesthetic blockade. Sympathetic fibers (thin, myelinated when entering 
the sympathetic trunk) tend to be blocked with the lowest concentration of 
drug, followed by pain, touch, and finally motor fibers. 
NERVE IMPULSE PHYSIOLOGY 
Nerve conduction involves the propagation of an electrical impulse 
created by the rapid movement of ions across the nerve cell membrane, 
creating an action potential. The principal ions involved in generating the 
action potential are sodium and potassium. The concentration of sodium is high 
extracellularly and low intracellularly. The opposite is true of potassium (high 
intracellularly, low extracellularly). 
At rest, the cell is more permeable to the positively charged cation 
potassium. The leakage of a positively charged ion leaves the inside of the cell 
more negative than the outside of the cell, creating a negative resting 
membrane potential of –60 to –70 mV. The sodium–potassium pump actively 
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transports sodium ions out of the cell and potassium into the cell to maintain 
the gradient at the resting level. 
Once chemical, mechanical, or electrical excitation occurs, an impulse is 
conducted along the nerve axon, causing depolarization of the nerve cell 
membrane. If the depolarization exceeds the threshold level (membrane 
potential of–60 mV), ion channels in the cell membranes open, allowing a 
sudden influx of sodium. The rapid influx of positively charged sodium ions 
causes depolarization of the cell. The influx of positively charged ions alters 
the membrane potential to become positive (above +30 mV). When the 
membrane potential exceeds approximately −30 mV, the sodium channels 
close, abating the influx of sodium into the cell. Depolarization generates a 
current that causes further depolarization of adjacent segments of the nerve, 
allowing the action potential to spread along the entire length of the nerve. The 
cell attempts to return to its resting potential with the efflux of potassium, 
thereby making the membrane potential less positive (repolarization). Baseline 
concentration gradients are eventually reestablished by the sodium–potassium–
ATP-ase pump. 
The rapid influx of sodium that leads to depolarization of the nerve 
occurs through specific channels in the cell membrane. The sodium channel is 
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a path that changes the nerve from nonconductive to conductive of an action 
potential (referred to as gated channels). If the change in conductance is 
created by electrical changes, the channel is called a voltage-gated channel. 
The voltage-gated sodium channel in the nerve is considered to be the site of 
action for local anesthetics. 
ACTION OF LOCAL ANESTHETICS  
Local anesthetic binds to sodium channels, primarily in the inactivated 
state, preventing further channel activation. Sodium ion movement into the cell 
is prevented, effectively blocking the development of the action potential. The 
resulting resting membrane potential is unaffected by further nerve stimulation, 
referred to as membrane stabilization of local anesthetics. 
MECHANISM OF ACTION OF LOCAL ANESTHETICS IN NEURAL 
BLOCKADE: 
Within the dorsal horn, local anesthetics can block both sodium and 
potassium ion channels in the dorsal horn neurons, inhibiting the generation 
and propagation of pain signals (nociceptive electrical activity). Motor 
blockade occurs from a similar action on the ventral horn neurons. Blockade of 
calcium ion channels in the spinal cord leads to resistance of electrical 
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stimulation from nociceptive afferent nerves, creating an intense analgesic 
action seen in centrally administered local anesthetics. 
In addition to ion channel alterations in the central neuraxis, epidurally 
administered local anesthetics indirectly inhibit the release of substance P and 
other neurotransmitters involved in pain signal processing. Substance P is 
involved in pain transmission from the presynaptic terminals of dorsal root 
ganglionic cells. The putative effects of centrally administered local anesthetics 
on substance P and these other transmitters is linked to the presynaptic 
blockade of the voltage-gated calcium channel. When calcium entry is blocked 
at the presynaptic level, release of these neurotransmitters (glutamate, 
substance P, calcitonin gene-related peptide [CGRP], neurokini-1 and -2 [NK1, 
NK2]) at the presynaptic level does not occur. Therefore, epidurally 
administered local anesthetics can indirectly inhibit pain signal transmission. 
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ROPIVACAINE PHARMACOLOGY:  
Ropivacaine is a long acting ,enantiomerically pure (S-enantiomer) 
amide local anesthetic. It is the propyl analogue of bupivacaine with high pKa 
and low lipid solubility. 
PHARMACOKINETICS: 
The pKa is 8.07, protein binding is 90-94%, while its partition 
coefficient is 147 and molecular weight is 328.89.this agent is 30% more 
potent than bupivacaine and CC:CNS ratio is 5:1 
PHARMACODYNAMICS: 
Ropivacaine has significantly better sensory-motor differentiation due to 
lower lipid solubility and so blocks nerve fibres involved in pain transmission 
(A delta and C fibres) to a greater degree than those controlling motor function 
( A beta fibres). Its onset time and duration are comparable to bupivacaine but 
with less cardiotoxicity due to the fact that it dissociates from sodium channels 
more rapidly and produces less accumulation of sodium channel.ropivacaine 
has mild intrinsic vasoconstricing properties, so it is unsuitable for infiltration 
in tissues without collateral blood supply and is the reason for longer cutaneous 
anesthesia. 
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STRUCTURAL FORMULA OF ROPIVACAINE: 
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DEXMETOMIDINE: 
HISTORY  
The α2-adrenergic agonists provide sedation, anxiolysis, hypnosis, 
analgesia, and sympatholysis. Dexmedetomidine is a more selective α2 agonist 
with a 1600 greater selectivity for the α2 receptor compared with the α1 
receptor.  
PHYSICOCHEMICAL CHARACTERISTICS  
Dexmedetomidine is the d-enantiomer of medetomidine, a substance that 
has been used for sedation and analgesia in veterinary medicine for many 
years. It shows a high ratio of specificity for the α2 receptor (α2/α1 1600:1) 
compared with clonidine (α2/α1 200:1), making it a complete α2 agonist. 
Dexmedetomidine belongs to the imidazole subclass of α2 receptor agonists, 
similar to clonidine. 
STRUCTURAL FORMULA OF DEXMEDETOMIDINE: 
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METABOLISM AND PHARMACOKINETICS  
Dexmedetomidine is rapidly distributed and extensively metabolized in 
the liver and excreted in urine and feces. Dexmedetomidine is 94% protein 
bound, and its concentration ratio between whole blood and plasma is 0.66 and 
displays nonlinear pharmacokinetics.. These pharmacokinetic parameters 
apparently are unaltered by age or weight or renal failure, but clearance is a 
function of height. The elimination half-life of dexmedetomidine is 2 to 3 
hours.  
PHARMACOLOGY  
Dexmedetomidine is a nonselective α2 agonist. Alpha2 adrenoreceptors 
are membrane-spanning G proteins. Intracellular pathways include inhibition 
of adenylate cyclase and modulation of ion channels. These receptors are 
involved in the sympatholysis, sedation, and antinociception effects of α2 
adrenoreceptors. 
EFFECTS ON THE CENTRAL NERVOUS SYSTEM  
The α2 agonists produce their sedative-hypnotic effect by an action on α2 
receptors in the locus caeruleus and an analgesic action at α2 receptors within 
the locus caeruleus and within the spinal cord. Despite sound levels of sedation 
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with dexmedetomidine, there is limited respiratory depression, providing wide 
safety margins. The α2 agonists have the advantage that their effects are readily 
reversible by α2-adrenergic antagonists (e.g., atipamezole).Dexmedetomidine 
reduced the intracerebral catecholamine outflow during injury and resulted in 
less neural tissue damage with better neurologic outcome. 
EFFECTS ON THE RESPIRATORY SYSTEM  
Dexmedetomidine at concentrations producing significant sedation 
reduces minute ventilation, but retains the slope of the ventilatory response to 
increasing carbon dioxide. Dexmedetomidine also exhibited a hypercarbic 
arousal phenomenon, which has been described during normal sleep and is a 
safety feature.  
EFFECTS ON THE CARDIOVASCULAR SYSTEM  
The basic effects of α2 agonists on the cardiovascular system are 
decreased heart rate; decreased systemic vascular resistance; and indirectly 
decreased myocardial contractility, cardiac output, and systemic blood 
pressure. Infusion of dexmedetomidine  also has been shown to result in a 
compensated reduction in systemic sympathetic tone without changes in 
baroreflex sensitivity.   
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INTRODUCTION TO CLINICAL STUDY 
 The α2-adrenergic agonists provide sedation, anxiolysis, hypnosis, 
analgesia, and sympatholysis. Dexmedetomidine shows a high ratio of 
specificity for the α2 receptor (α2/α1-1600:1) compared with clonidine         
(α2/α1-200:1), making it a complete α2 agonist [27]. 
Alpha2 agonists do have an analgesic effect when injected via the 
intrathecal or epidural route [4,5,6]. Intrathecally injected dexmedetomidine in 
sheep reduces blood pressure in 1 minute. When dexmedetomidine is injected 
into the epidural space, it rapidly diffuses into the CSF (in one study, 22% of 
the injected dose was identified in the CSF). The effects on blood pressure are 
slower in onset with an epidural injection than with an intrathecal 
administration. Epidural effects are seen in 5 to 20 minutes. The primary site of 
analgesic action is thought to be the spinal cord [5,6].  
In humans, dexmedetomidine was first administered epidurally in 1997, 
combined with lidocaine 1.5 % in patients undergoing hysterectomy, 
prolonging postoperative analgesia [6]. Based on studies with clonidine [7.8], 
we evaluated the synergism of dexmedetomidine with ropivacaine during 
epidural administration, in improving the characteristics of anesthesia. The aim 
of this study was to evaluate the clinical effects of Dexmedetomidine added to 
ropivacaine on the characteristics of epidural anesthesia.  
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METHODOLOGY  
After approval of the study protocol by the Ethics committe and 
obtaining informed consent. It was a comparative, double blind, randomized, 
controlled study and distribution by means of a draw with a sealed envelope. 
 
Patients were admitted to the hospital, after a period of absolute fasting at 
least 8 hours, without administering premedication. venipuncture was 
performed with an 18G catheter for administration of Ringer's lactate,   8 ml.kg-
1. h-1. Monitoring consists of, Pulse oximetry (SpO2), NIBP,ECG. persons not 
directly involved in the anesthetic prepared dexmedetomidine or sodium 
chloride 0.9%, 1 ml syringe . Epidural puncture was performed with a 18G 
Tuohy needle, through the lumbar epidural space, with patients in sitting 
position, through loss of resistance technique.Patients were sedated on demand 
basis with pentazocine or midazolam.  
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All patients received an epidural:  
Control Group (n = 20): 1 ml of sodium chloride 0.9 % (placebo); 
Dexmedetomidine group (n = 20): 1 μg.kg-1 + dexmedetomidine solution of 
sodium chloride 0.9 %, so that the volume was completed in 1 ml syringe. 
Immediately after the injection of the study drug, all patients were administered 
20 ml of 0.75% (150 mg), the rate of 1 ml every three seconds.  
After the surgery, patients were referred to the recovery room, where 
they remained for a period, until there was complete recovery of sensory and 
motor block.All were monitored with Pulse oximetry (SpO2), 
NIBP,ECG.Patients who complained of pain were given rescue post-operative 
analgesia with 10ml of 0.2% Ropivacaine through epidural route. 
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DEFINITION OF VARIABLES:  
SENSORY BLOCK ONSET TIME 
Time interval between end of anesthetic injection and appearance of 
cutaneous analgesia in dermatomes T-12, T-10, T-8, T-6 
DURATION OF MOTOR BLOCK 
Administration of anesthetic and attainment of grade 0 in Bromage 
motor scale 
DURATION OF ANALGESIA 
Administration of anesthetic and disappearance of cutaneous level at 
each dermatomal level 
POST-OP ANALGESIA DURATION  
Administration of anesthetic and time of analgesic usage in PACU 
SUPPLEMENTAL SEDATION 
If patient felt pain or uncomfortable , with pentazocine 0.3mg/kg and or 
midazolam 0.02mg I.V 
If there were hypotension, (measured as systolic blood pressure less than 
30 % of its initial value or below 90 mmHg) during anesthesia, it was treated 
     52 
   
 
with administration of ephedrine, 6 to 12 mg and increased administration of 
intravenous fluids.  
Bradycardia(heart rate<45) were treated with atropine, 0.6 mg , and 
administration of oxygen via face mask (4 l.min-1), if SpO2 was < 94%.  
STATISTICAL ANALYSIS:  
It’s a double blind randomized controlled clinical study 
Variables were analysed with Student‘t’ test, Chi Square test 
Variables like age, sex, weight, height were compared using Levene’s  
test for equality of variance 
Sample size obtained according to previous background study  
‘p’ value less than 0.05 was taken as significant 
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RESULTS  
One patient in the control group excluded for failure of epidural and 
need for general anesthesia. 
There was no significant difference between groups in distributions of 
age, weight, height and sex, type of surgery or duration of surgery. 
VARIABLES    CONTROL DEX 
Age 42.25 39.1 
Sex 
Female 3 4 
Male 17 16 
Height (cm) 169.4 163.2 
Weight (kg) 69.95 66.75 
Level Of Epidural 
L1-L2 2 2 
L2-L3 10 10 
L3-L4 8 8 
Cathetar Length (cm) 6.5 6.85 
Surgery 
IM / IL Nailing 10 9 
Illizarao ring fixation 4 2 
DHS 2 5 
TKR 1 1 
THR 1 0 
DCS 0 1 
Encirclage / TBW L Patella 1 0 
Plate & Screw fixation 0 2 
Hemiarthroplasty  1 0 
ASA 
I 12 15 
II 8 5 
DURATION OF SURGERY (mins) 158.3 177 
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Regarding block onset time (time to attain analgesia at T12,T10,T8,T6), 
dex group has slightly shortented onset time with less significance when 
compared to control group(13.90mins vs 12.45mins) p<0.08 
 
 
 
 
 
 
 
 
 
 
 
     55 
   
 
Regarding the upper level of analgesia, examined after an hour after 
epidural, all patients did attain T6 level without any significance between 
groups 
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Regarding the duration of analgesia, the group receiving 
dexmedetomidine had significantly higher compared to the control group. In 
dex group it is 304.25mins compared to 236.35 in control group (p<0.02) and 
two segment regression time was prolonged in dex group. 
Independent Samples Test 
  t-test for Equality of Means 
  
Df 
Sig. (2-
tailed) 
Mean 
Difference 
ANALGESIA 
DURATION  MINUTES 
Equal variances assumed 38 .000 -67.900
Equal variances not assumed 37.821 .000 -67.900
 
 
  Levene's Test for 
Equality of 
Variances 
t-test for Equality 
of Means 
  F Sig. T 
REGRESSION TIME  T6-
T10 MINUTES 
Equal variances assumed 1.614 .212 -12.787
Equal variances not assumed   -12.787
REGRESSION TIME  
T10-12 MINUTES 
Equal variances assumed 4.076 .051 -.394
Equal variances not assumed   -.394
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Regarding motor block duration, dex group showed significant 
prolongation in duration(248mins) when compared to control group 
(204.65mins), level of significance p<0.04, slightly increased intensity of 
blockade assessed by Bromage motor scale was observed with dex group, but 
without much significance p<0.37. 
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The duration of postoperative analgesia was significantly different 
between groups ( p < 0.001) , and the dexmedetomidine group had a duration 
of analgesia which is 60% more than control group. Values in minutes as an 
average were 496.95mins for dex group when compared to 309mins in control 
group. 
Independent Samples Test 
  t-test for Equality of Means 
  Df Sig. (2-tailed) Mean Difference
POST OF ANALGESIS IN 
MINUTES. 
Equal variances assumed 38 .000 -187.450
Equal variances not assumed 32.091 .000 -187.450
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The occurrence of hypotension and the need for vasopressors in the intra 
-and postoperatively was similar between groups , with no significant 
difference p>0.13.Both groups showed excellent hemodynamic stability with 
less incidence of hypotension or bradycardia.The need for sedation was 
decreased in dex group when compared to control groups. 
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DISCUSSION 
In this study, the effect of added dexmedetomidine to epidural 
ropivacaine was evaluated. The results showed duration of analgesia, motor 
block duration and post-operative analgesia were significantly increased and 
there is clear synergism between dexmedetomidine and ropivacaine when 
administered epidurally. 
Previous studies evaluated the effect of α2 agonist added with various 
local anesthetics.This study conducted based on previous studies with epidural 
clonidine[8,10,11],which prolongs post operative analgesia[12,14,15]. 
  Dexmedetomidine is a nonselective α2 agonist. Three subtypes of α2 
adrenoreceptors have been described in humans: α2A, α2B, and α2C.[27,30].The 
α2A adrenoreceptors are primarily distributed in the periphery, whereas α2B and 
α2C are in the brain and spinal cord. Postsynaptic located α2 adrenoreceptors in 
peripheral blood vessels produce vasoconstriction, whereas presynaptic α2 
adrenoreceptors inhibit the release of norepinephrine, potentially attenuating 
the vasoconstriction. The overall response to α2 adrenoreceptors agonists is 
related to the stimulation of α2 adrenoreceptors located in the CNS and spinal 
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cord. These receptors are involved in the sympatholysis, sedation, and 
antinociception effects of α2 adrenoreceptors. 
Ropivacaine is a long acting amide local anesthetics and ‘S’ isomer of 
the propyl analogue of mepivacaine and bupivacaine. It has similar properties 
to bupivacaine , but with better cadiotoxicity profile because it dissociates from 
Na+channels more rapidly and produces less accumulation of Na+channel 
block.Significantly better sensory-motor differentiation,due to lower lipid 
solubility than bupivacaine Has mild intrinsic vasoconstricting properties and 
so unsuitable for infiltration in tissues without collateral blood supply and is 
the reason for longer cutaneous anesthesia.Ropivacaine pKa is 8.07, Protein 
binding is 94%, Partition co-efficient is 11, CC:CNS ratio is 5:1, Potency 4. 
Dexmedetomidine is an agonist of α2 adrenergic receptor – agonist 
where ratio among  α2 : α1  is 1600:1.Dex epidural effect is dose dependent and 
superior than I.V due to its high affinity for  α2 adrenergic receptors in spinal 
cord. After epidural administration of Dex, it is rapidly detected in CSF within 
five mins, however only 22% is absorbed into intra thecal space [19,31,33]. Its 
anti-nociceptive effect is dose dependent and is related to affinity of located α2  
adrenergic receptors in spinal cord and higher lipid solubility and penetration 
of meninges[5,20].Prolonged analgesic action of local anesthetics in epidural 
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space  is due to reduced systemic absorbtion caused by local vasoconstriction 
mediated by α2C  adrenergic receptors in smooth muscle of epidural venous 
plexus[11,21,27]. 
The α2 agonists produce their sedative-hypnotic effect by an action on α2 
receptors in the locus caeruleus and an analgesic action at α2 receptors within 
the locus caeruleus and within the spinal cord [28, 33, 34]. During epidural 
administration cephalad spread of the drug into meninges may be responsible 
for sedation [16,22].The α2 agonists act through the endogenous sleep-
promoting pathways to exert their sedative effect . Dexmedetomidine produces 
a decrease in activity of the projections of the locus caeruleus to the 
ventrolateral preoptic nucleus. This increases GABAergic and galanin release 
in the tuberomammillary nucleus, producing a decrease in histamine release in 
cortical and subcortical projections. 
Dexmedetomidine at concentrations producing significant sedation 
reduces minute ventilation, but retains the slope of the ventilatory response to 
increasing carbon dioxide. Dexmedetomidine also exhibited a hypercarbic 
arousal phenomenon, which has been described during normal sleep and is a 
safety feature. IV or inhaled dexmedetomidine has been implicated in blocking 
histamine-induced bronchoconstriction in dogs [22].                   
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Another advantage is that their effects are easily reversible with alpha-2-
adrenergic agonists such as atipamazole (with an affinity for the receptors of 
60:1, compared to dexmedetomidine), which is the dependent dose, it rapidly 
reverses the sedation and cardiovascular effects at doses from 15 to 150 
micg/kg[29]. 
The basic effects of α2 agonists on the cardiovascular system are 
decreased heart rate; decreased systemic vascular resistance; and indirectly 
decreased myocardial contractility, cardiac output, and systemic blood 
pressure.Bradycardia and hypotension  with administration of 
dexmedetomidine is dose dependent and occurs in epidural if level is higher 
[19,21,22,24]. Shivering incidence may be reduced with α2 agonists due to 
central inhibition of thermoregulatory centre [23,25,26]  
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CONCLUSION 
We conclude that dexmedetomidine at a dose of 1 μg.kg-1 acts 
synergistically with ropivacaine 0.75% in epidural anesthesia. The drug 
increases the duration of analgesia, motor block duration, prolongs the duration 
of postoperative analgesia and decreases sedative usage and shivering episodes. 
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REVIEW OF LITERATURE 
1. Fukushima K, Nishime Y, Mori K, Kaneko I, Fukushima Y.- The 
pioneering use of dexmedetomidine epidurally in humans occurred in 
1997,  in which dexmedetomidine at a dose of 2 μg.kg-1 was combined 
with lidocaine 1.5% in total dose of 225 mg in patients anesthetized with 
isoflurane and underwent hysterectomy. The authors found that the 
duration of postoperative analgesia was doubled by dexmedetomidine, 
compared with only the administration of epidural lidocaine 
2. Aantaa R, Jaakola ML, Kallio A, Kanto J. et al suggested that alpha 2-
Adrenergic agonists have been shown to reduce anesthetic requirements 
of other anesthetics and concluded that with the high dose of 
dexmedetomidine, the MAC of isoflurane was 47% less than that 
without dexmedetomidine. 
3. Lima OS, Neto DSC, Araujo GS Jr, Benevides AM et al In a 
comparative study, administration of clonidine, 150 micrograms, or 
dexmedetomidine, 100 micrograms, associated with ropivacaine 1% in 
total dose of 200 mg,  resulted in no significant difference in onset time 
of sensory block10.Moreover, it was found, with the administration of 
dexmedetomidine, a significant increase of the duration of analgesic 
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block in dermatomes T10 and T12. There was also enhancement of the 
intensity of motor block and duration of this blockage caused by 
dexmedetomidine. Similar to the increased length of anesthesia, 
dexmedetomidine also promoted a significant increase of the duration of 
postoperative analgesia. 
4. Silva et al. In 2002, also found post-operative analgesic action of 
dexmedetomidine in additional fixed dose of 100 mg when administered 
in combination with bupivacaine 0.5% in patients undergoing 
hysterectomy under epidural anesthesia.  
5. Maroof et al. Studying patients undergoing orthopedic surgical 
procedures, found a higher incidence of bradycardia associated when 
dexmedetomidine, 2 μg.kg-1, 0.5% bupivacaine epidural anesthesia 
compared with the separate administration of bupivacaine. However, no 
significant difference in blood pressure was observed.they suggested that 
dexmedetomidine at a dose of 2 μg.kg-1 plus bupivacaine 0.5% epidural 
anesthesia significantly reduced the incidence of shivering, an effect that 
is mainly due to central inhibition of thermoregulatory control . 
6. Ala-Kokko TI, Pienimaki P, Lampel And Hollmen AI, Pelkonen O, 
Vahakangas K.et al in their study, ”Transfer of clonidine and 
dexmedetomidine across the isolated perfused human 
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placenta”,suggested that enhanced analgesic potency of 
dexmedetomidine compared with clonidine, when injected epidurally, 
due not only to its greater selectivity for alpha 2 receptors , but probably 
also to higher lipid solubility and penetration into the meninges. 
7. Eisenach JC, Shafer SL, Bucklin BA, Jackson C, Kallio A. et al in their 
animal study, ”Pharmacokinetics and pharmacodynamics of intraspinal 
dexmedetomidine in sheep”, suggested that in sheep, after the epidural 
administration of dexmedetomidine it is rapidly detected in the 
cerebrospinal fluid, reaching maximum concentration after five minutes. 
Only 22% of the injected dose was identified in the CSF  ,and concluded 
that primary spinal site of action for decreased blood pressure after 
intraspinal dexmedetomidine injection. 
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STATISTICS 
AGE: 
 
Group Statistics 
 GROUP N Mean Std. Deviation Std. Error Mean 
AGE 1 20 42.25 14.145 3.163
2 20 39.10 14.836 3.317
 
 
 
HEIGHT & WEIGHT: 
 
Group Statistics 
 GROUP N Mean Std. Deviation Std. Error Mean 
WEIGHT 1 20 69.95 7.944 1.776
2 20 66.75 7.181 1.606
HEIGHT 1 20 169.35 6.761 1.512
2 20 163.15 9.161 2.048
 
 
  
] 
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CATHETAR LENGTH IN EPIDURAL SPACE: 
 
Group Statistics 
 GROUP N Mean Std. Deviation Std. Error Mean 
CATHETAR LENGTH IN  
CENTIMETERS 
1 20 6.50 .827 .185
2 20 6.85 .813 .182
 
 
 
 
 
DURATION OF SURGERY: 
Group Statistics 
 GROUP N Mean Std. Deviation Std. Error Mean 
DURATION OF SURGERY 
IN MINUTES 
1 20 158.25 22.553 5.043
2 20 177.00 29.037 6.493
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BLOCK ONSET TIME: 
 
Group Statistics 
 GROUP N Mean Std. Deviation Std. Error Mean 
BLOCK ONSET TIME  T 12 1 20 13.90 2.713 .607
2 20 12.45 2.460 .550
BLOCK ONSET  TIME  T10 1 20 26.85 4.522 1.011
2 20 25.90 3.932 .879
BLOCK ONSET TIME  T8 1 20 42.30 5.352 1.197
2 20 42.45 4.673 1.045
BLOCK ONSET TIME  T6 1 20 62.40 7.632 1.707
2 20 66.65 7.534 1.685
BLOCK ONSET TIME T4 1 2 70.00 .000a .000
2 2 70.00 .000a .000
A. t cannot be computed because the standard deviations of both groups are 0. 
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REGRESSION TIME: 
Group Statistics 
 GROUP N Mean Std. Deviation Std. Error Mean 
REGRESSION TIME  T6-T10 
MINUTES 
1 20 115.55 12.361 2.764
2 20 177.30 17.708 3.960
REGRESSION TIME  T10-12 
MINUTES 
1 20 57.25 11.516 2.575
2 20 58.45 7.244 1.620
 
 
 
Independent Samples Test 
  Levene's Test for Equality of 
Variances 
t-test for Equality 
of Means 
  F Sig. T 
REGRESSION TIME  T6-
T10 MINUTES 
Equal variances assumed 1.614 .212 -12.787
Equal variances not assumed   -12.787
REGRESSION TIME  T10-
12 MINUTES 
Equal variances assumed 4.076 .051 -.394
Equal variances not assumed   -.394
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Independent Samples Test 
  t-test for Equality of Means 
  df Sig. (2-tailed) Mean Difference
REGRESSION TIME  T6-T10 
MINUTES 
Equal variances assumed 38 .000 -61.750
Equal variances not assumed 33.962 .000 -61.750
REGRESSION TIME  T10-12 
MINUTES 
Equal variances assumed 38 .695 -1.200
Equal variances not assumed 32.000 .696 -1.200
 
 
Independent Samples Test 
  t-test for Equality of Means 
  
 
95% Confidence Interval of the 
Difference 
  Std. Error 
Difference Lower Upper 
REGRESSION TIME  T6-
T10 MINUTES 
Equal variances assumed 4.829 -71.526 -51.974
Equal variances not assumed 4.829 -71.564 -51.936
REGRESSION TIME  T10-
12 MINUTES 
Equal variances assumed 3.042 -7.358 4.958
Equal variances not assumed 3.042 -7.397 4.997
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 ANALGESIA DURATION: 
 
Group Statistics 
 GROUP N Mean Std. Deviation Std. Error Mean 
ANALGESIA DURATION  
MINUTES 
1 20 236.35 20.704 4.630
2 20 304.25 19.325 4.321
 
Independent Samples Test 
  Levene's Test for Equality of 
Variances 
t-test for Equality 
of Means 
  F Sig. T 
ANALGESIA DURATION  
MINUTES 
Equal variances assumed .426 .518 -10.722
Equal variances not assumed   -10.722
 
Independent Samples Test 
  t-test for Equality of Means 
  df Sig. (2-tailed) Mean Difference
ANALGESIA DURATION  
MINUTES 
Equal variances assumed 38 .000 -67.900
Equal variances not assumed 37.821 .000 -67.900
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MOTOR BLOCK DURATION: 
 
Group Statistics 
 GROUP N Mean Std. Deviation Std. Error Mean 
MOTOR BLOCK  DURATION 
IN MINUTES 
1 20 204.65 13.922 3.113
2 20 248.00 28.442 6.360
 
Independent Samples Test 
  Levene's Test for Equality of 
Variances 
t-test for Equality 
of Means 
  F Sig. T 
MOTOR BLOCK  
DURATION IN MINUTES 
Equal variances assumed 14.025 .001 -6.122
Equal variances not assumed   -6.122
 
 
Independent Samples Test 
  t-test for Equality of Means 
  df Sig. (2-tailed) Mean Difference
MOTOR BLOCK  
DURATION IN MINUTES 
Equal variances assumed 38 .000 -43.350
Equal variances not assumed 27.610 .000 -43.350
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INTRA OP HEMODYNAMICS: 
PULSE RATE INTRA-OP: 
 
 
 
 
 
 
 
 
 
 
 
 
Group Statistics 
 GROUP N Mean Std. Deviation Std. Error Mean
INTRA OP HEMODYNAMICS-PR-1 
MINUTES 
1 20 87.85 12.609 2.819
2 20 83.60 12.015 2.687
INTRA OP HEMODYNAMICS-PR-5 
MINUTES 
1 20 86.65 13.132 2.936
2 20 81.60 13.438 3.005
INTRA OP HEMODYNAMICS-PR-15 
MINUTES 
1 20 86.60 14.558 3.255
2 20 81.60 14.140 3.162
INTRA OP HEMODYNAMICS-PR-30 
MINUTES 
1 20 88.20 17.225 3.852
2 20 80.90 14.101 3.153
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SYSTOLIC BP INTRA-OP: 
  
  
   
   
  
  
  
  
 
 
Group Statistics 
 GROUP N Mean Std. Deviation Std. Error Mean 
INTRA OP HEMODYNAMIC 
SYSTOLIC BP 1 MINUTES 
1 20 131.15 12.525 2.801
2 20 125.50 10.501 2.348
INTRA OP HEMODYNAMIC 
SYSTOLIC BP 5 MINUTES 
1 20 126.95 12.951 2.896
2 20 122.25 9.267 2.072
INTRA OP HEMODYNAMIC 
SYSTOLIC BP 15 MINUTES 
1 20 125.50 16.340 3.654
2 20 116.65 13.172 2.945
INTRA OP HEMODYNAMIC  
SYSTOLIC BP 30 MINUTES 
1 20 119.80 16.932 3.786
2 20 111.40 15.736 3.519
INTRA OP HEMODYNAMIC  
SYSTOLIC BP  60 MINUTES 
1 20 120.60 14.773 3.303
2 20 112.00 13.219 2.956
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Group Statistics 
DIASTOLIC BP INTRA-OP: 
 GROUP N Mean Std. Deviation Std. Error Mean 
INTRA OP HEMODYNAMIC 
DIASTOLIC BP 1 MINUTES 
1 20 83.00 7.384 1.651
2 20 81.50 6.708 1.500
INTRA OP HEMODYNAMIC 
DIASTOLIC BP 5 MINUTES 
1 20 83.00 7.384 1.651
2 20 81.50 6.708 1.500
INTRA OP HEMODYNAMIC 
DIASTOLIC BP 15 MINUTES 
1 20 81.55 8.095 1.810
2 20 77.55 8.959 2.003
INTRA OP HEMODYNAMIC 
DIASTOLIC BP 30 MINUTES 
1 20 80.60 10.763 2.407
2 20 72.50 18.749 4.192
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POST OP ANALGESISA DURATION: 
Group Statistics 
 GROUP N Mean Std. Deviation Std. Error Mean 
POST OP ANALGESIS IN 
MINUTES. 
1 20 309.00 22.880 5.116
2 20 496.45 36.200 8.095
 
Independent Samples Test 
  
Levene's Test for Equality of 
Variances 
t-test for 
Equality of 
Means 
  F Sig. t 
POST OP ANALGESIS IN 
MINUTES. 
Equal variances assumed 4.085 .050 -19.575
Equal variances not assumed   -19.575
 
Independent Samples Test 
  t-test for Equality of Means 
  df Sig. (2-tailed) Mean Difference
POST OP ANALGESIS IN 
MINUTES. 
Equal variances assumed 38 .000 -187.450
Equal variances not assumed 32.091 .000 -187.450
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INTENSITY OF MOTOR BLOCK: 
INTENSITY MOTOR BLOCK 45 MINUTES * GROUP 
   GROUP  
   1 2 Total 
INTENSITY MOTOR BLOCK 
45 MINUTES 
1 Count 0 2 2
% within GROUP .0% 10.0% 5.0%
2 Count 20 18 38
% within GROUP 100.0% 90.0% 95.0%
 Total Count 20 20 40
% within GROUP 100.0% 100.0% 100.0%
 
Chi-Square Tests 
 
Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 2.105a 1 .147   
Continuity Correctionb .526 1 .468   
Likelihood Ratio 2.878 1 .090   
Fisher's Exact Test    .487 .244
Linear-by-Linear Association 2.053 1 .152   
N of Valid Cases 40     
A. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 1.00. 
B. Computed only for a 2x2 table 
 
 
     80 
   
 
BIBLIOGRAPHY 
1. Aantaa R, Jaakola ML, Kallio A, Kanto J. Reduction of the minimum 
alveolar concentration of isoflurane by dexmedetomidine. 
Anesthesiology. 1997 
2. Jalonen J, Hynynen M, Kuitunen A, Heikkila H, J Perttila, Salmenpera 
M, et al. Dexmedetomidine an anesthetic adjunct in the coronary artery 
bypass grafting . Anesthesiology. 1997 
3. Unlugenc H, Gunduz M, Guler T, Yagmur O, Isik G. The effect of pre- 
administration of intravenous Anaesthetic dexmedetomidine on 
postoperative pain in Patients receiving patient -controlled morphine. 
Eur J Anaesthesiol . 2005 
4. Meert TF, De Kock M. Potentiation of the analgesic properties of 
fentanyl opioids with alpha -like2-adrenoceptor agonists in rats. 
Anesthesiology. 1994 
5.  T, Dohi S, Ohta, Shimonaka H, Iida H. Antinociception by epidural and 
systemic alpha (2)- adrenoceptor agonists and Their binding affinity in 
rat spinal cord and brain . Analg. 2000 
     81 
   
 
6. Fukushima K, Nishime Y, Mori K, Kaneko I, Fukushima Y. 
Postoperative analgesic action and plasma concentration of epidural 
dexmedetomidine administered. Anesthesiology. 1997 
7. Klimscha W , Chiari A, Krafft P, Plattner O, Taslimi R, Mayer N, et al. 
Hemodynamic and analgesic effects of clonidine added repetitively to 
continuous epidural and spinal blocks. Analg. 1995 
8. Alves TCA, Braz JRC. Effects of the combination of clonidine to 
ropivacaine for epidural anesthesia. Anesth Analg . 2002 
9. Bromage PR. A comparison of the hydrochloride and carbon dioxide 
salts of lidocaine and prilocaine in epidural analgesia. Acta Anaesthesiol 
Scand. 1965 
10. Lima OS, Neto DSC , Araujo GS Jr , Benevides AM. Comparative study 
of epidural anesthesia with 1% ropivacaine combined with clonidine or 
dexmedetomidine. Anesth Analg . 2003 
11. Nishikawa T, Dohi S. Clinical evaluation of clonidine added to lidocaine 
solution for epidural anesthesia. Anesthesiology. 1990 
12. Milligan KR, Convery PN, Weir P, Quinn P, Connolly D. The efficacy 
and safety of epidural infusions of levobupivacaine with and without 
clonidine for postoperative pain relief in Patients Undergoing total hip 
replacement. Analg. 2000 
     82 
   
 
13. Landau R, Schiffer E, Morales M, Savoldelli G, Kern C. The dose- 
sparing effect of clonidine added to ropivacaine for labor epidural 
analgesia. Analg. 2002 
14. Curatolo M, Schnider TW, Petersen- Felix S , Weiss S, Signer C, 
Scaramozzino P, et al. A direct search procedure to optimize 
combinations of epidural bupivacaine, fentanyl, and clonidine for 
postoperative analgesia. Anesthesiology. 2000 
15. Paech MJ, Pavy TJ, Orlikowski CE , Lim W, Evans SF. Postoperative 
epidural infusion : a randomized , double-blind , dose -finding trial of 
clonidine in combination with bupivacaine and fentanyl. Analg. 1997 
16. Walker SM , Howard RF, Keay KA , Fitzgerald M. Developmental age 
influences the effect of epidural dexmedetomidine on inflammatory 
hyperalgesia in rat pups . Anesthesiology. 2005 
17. Muguruma T, Sakura S , Saito Y. Dexmedetomidine and bupivacaine 
Have synergistic antinociceptive interaction in rats . Anesthesiology. 
2006 
18. Silva VM, Araújo JHL , Baldiotti LAS. epidural bupivacaine with 
Dexmedetomidine for hysterectomy. Anesth Analg . 2002 
     83 
   
 
19. JC, Shafer SL, Bucklin BA , Jackson C, Kallio A. Pharmacokinetics and 
pharmacodynamics of intraspinal dexmedetomidine in sheep. 
Anesthesiology. 1994 
20. Ala- Kokko TI, Pienimaki P, Lampel And Hollmen AI, Pelkonen O, 
Vahakangas K. Transfer of clonidine and dexmedetomidine across the 
isolated perfused human placenta. Acta Anaesthesiol Scand. 1997 
21. JC, De Kock M, Klimscha W. Alpha (2)- adrenergic agonists for 
regional anesthesia. A clinical review of clonidine (1984-1995) . 
Anesthesiology. 1996 
22. Sabbe MB, Penning JP, Ozaki GT, Yaksh TL. Spinal and systemic 
action of the alpha 2 receptor agonist dexmedetomidine in dogs . 
Antinociception and carbon dioxide response. Anesthesiology. 1994 
23. Maroof M , Khan SA , Jain D , Khan RM, Maroof MS. Evaluation of 
effect of dexmedetomidine in Reducing shivering Following epidural 
anesthesia. Anesthesiology. 2004 
24. Rauck RL , Eisenach JC , Jackson K , Young LD , Southern J. Epidural 
clonidine treatment for refractory reflex sympathetic dystrophy. 
Anesthesiology. 1993 
 
     84 
   
 
25. Talke P, Tayefeh F, Sessler DI , Jeffrey R, Noursalehi M , Richardson C. 
Dexmedetomidine does not alter the sweating threshold , But 
comparably and Linearly Decreases the vasoconstriction and shivering 
thresholds . Anesthesiology. 1997 
26. Douf AG , Lin CM , Suleman MI, Liem EB, Lenhardt R, Morioka N, et 
al. Dexmedetomidine and meperidine additively Reduce the shivering 
threshold in humans. Stroke. 2003 
27. Virtanen R, Savola JM, Saano V, Nyman L: Characterization of the 
selectivity, specificity and potency of medetomidine as an alpha 2-
adrenoceptor agonist.  Eur J Pharmacol  1988 
28. Nelson LE, Lu J, Guo T, et al: The alpha2-adrenoceptor agonist 
dexmedetomidine converges on an endogenous sleep-promoting 
pathway to exert its sedative effects. 
29. Aho M, Erkola O, Kallio A, et al: Comparison of dexmedetomidine and 
midazolam sedation and antagonism of dexmedetomidine with 
atipamezole.  J Clin Anesth  1993 
30. Reid K, Hayashi Y, Guo TZ, et al: Chronic administration of an alpha 2 
adrenergic agonist desensitizes rats to the anesthetic effects of 
dexmedetomidine.  Pharmacol Biochem Behav  1994 
     85 
   
 
31. Eisenach JC, De Kock M, Klimscha W: Alpha(2)-adrenergic agonists for 
regional anesthesia: A clinical review of clonidine (1984-1995). 
 Anesthesiology 1996 
32. Karhuvaara S, Kallio A, Salonen M, et al: Rapid reversal of alpha 2-
adrenoceptor agonist effects by atipamezole in human volunteers.  Br 
Clin Pharmacol  1991 
33. Guo TZ, Jiang JY, Buttermann AE, Maze M: Dexmedetomidine 
injection into the locus ceruleus produces antinociception. 
 Anesthesiology  1996 
34. Asano T, Dohi S, Ohta S, et al: Antinociception by epidural and 
systemic alpha(2)-adrenoceptor agonists and their binding affinity in rat 
spinal cord and brain.  Anesth Analg  2000 
 
 
 
 
 
 
 
 
 
     86 
   
 
PROFORMA 
 
NAME:    AGE/SEX:    IP NO.: 
DATE:     Wt.: Ht.:    GROUP: 
DIAGNOSIS: 
SURGERY: 
BRIEF HISTORY: 
COEXISTING ILLNESS: 
 
EXAMINATION: 
 PR:     CVS: 
 BP:     RS: 
 RR:     AIRWAY: 
 
INVESTIGATIONS: 
 Hb:         BLOOD UREA:    
  
 URINE ALB:      BLOOD SUGAR:    
   
        URINE SUGAR:      Sr. CREATININE:    
   
X-RAY CHEST:    Sr. ELECTROLYTES:  
ECG: 
 
ANESTHESIA DETAILS: 
 PREMEDICATION: 
 GROUP: 
 LEVEL OF EPIDURAL: 
 CATHETAR LENGTH IN EPIDURAL SPACE: 
 NO. OF ATTEMPTS: 
 DRUG DETAILS: 
DURATION OF SURGERY: 
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PARAMETERS OBSERVED 
 
 
BLOCK ONSET TIME:                               T-12               T10              T8                 T6 
 
 
UPPER LEVEL OF ANALGESIA&TIME: 
 
 
INTENSITY OF MOTOR BLOCK:    GRADE          0          1          2          3 
 
 
ANALGESIC & MOTOR BLOCK DURATION: 
 
 
SENSORY SCORE:                              0                      1                    2 
 
 
SEDATION SCORE: 
 
 
HEMO DYNAMICS: 
  
PARAMETERS 1 min 5 mins 15 mins 30 mins 1 Hr 2 Hrs 3 Hrs 
PR        
BP        
SpO2        
 
 
 
DURATION OF POST OP ANALGESIA:  
 
Master Chart (Control Group)
SI No. Group Name Date Age Sex Weight (kg)
Height 
(cm) Surgery ASA
DURATION 
OF SURGERY 
(mins)
Level Of 
Epidural
Cathetar 
Length (cm) T-12 (mins)
1 C  Sathish 12-5-2010 28 M 60 165 
Encirclage / TBW L 
Patella I 120 L3-L4 6 11
2 C  Joseph 12-5-2010 26 M 62 167 IM / IL Nailing I 195 L2-L3 6 16
3 C  Chandran 13-5-2010 35 M 75 180 IM / IL Nailing I  180 L3-L4 8 18
4 C  Rahim 13-5-2010 34 M 80 174 IM / IL Nailing I 150 L3-L4 7 12
5 C  Anandhan 26-5-2010 32 M 80 174 Illizarao ring fixation I  120 L2-L3 7 12
6 C  Udhayakumar 24-5-2010 21 M 68 170 IM / IL Nailing I 180 L1-L2 8 13
7 C  Pachiyappam 24-5-2010 55 M 60 170 Illizarao ring fixation II 150 L3-L4 7 13
8 C  Devi 2-6-2010 55 F 60 170 IM Nailing II 150 L2-L3 5 10
9 C  Damodharan 2-6-2010 55 M 73 175 IM Nailing II 180 L2-L3 6 19
10 C  Srivasan 10-6-2010 49 M 76 160 IM Nailing II 150 L2-L3 6 10
11 C  Brimadhanadan 16-6-2010 38 M 80 165 IM Nailing I 150 L2-L3 6 14
12 C  Sekar 16-6-2010 48 M 85 175 Hemiarthroplasty I 120 L2-L3 6 12
13 C  Subramani 21-6-2010 70 M 65 172 THR II  150 L2-L3 6 12
14 C  Karupusami 21-6-2010 52 M 73 174 Illizarao ring fixation II 150 L2-L3 6 14
15 C  Radha 3-5-2010 38 F 65 159 IM Nailing I 150 L3-L4 6 15
16 C  Ramesh 3-5-2010 23 M 65 179 IM Nailing I 180 L3-L4 7 17
17 C  Radhika 5-5-2010 32 F 58 153 DHS I 180 L2-L3 7 17
18 C  Ravi 19-5-2010 48 M 72 165 DHS II 180 L1-L2 8 16
19 C  Anbu Selvam 23-6-2010 38 M 70 170 Illizarao ring fixation I 180 L3-L4 6 11
20 C  Arumugam 20-5-2010 68 M 72 170 TKR II 150 L3-L4 6 16
B
T-10 (mins) T-8  (mins) T-6  (mins) T-4  (mins)
T-6 to T-10 
(mins)
T-10 to T-12 
(mins)
Analgesia 
duration 
(mins)
Motor Block 
Duration      
(mins) 45mins 120mins 180mins 240mins
1 mins 5 mins
34 48 56 106 46 208 210 2 3 1 1 75 70
33 42 55 104 46 205 195 2 3 1 0 95 90
29 45 65 112 52 229 190 2 3 1 0 89 85
22 42 58 118 76 252 195 2 3 1 1 70 65
23 38 55 126 76 257 205 2 3 2 1 80 85
29 41 67 125 80 272 210 2 3 2 1 85 89
32 42 55 70 98 56 224 225 2 3 2 1 86 86
20 34 45 102 64 211 215 2 3 2 1 86 90
22 40 70 133 53 256 220 2 3 2 1 86 90
22 36 55 120 56 231 205 2 3 2 1 60 55
32 55 70 125 72 267 210 2 3 2 1 86 82
20 34 62 117 63 242  200 2 2 1 1 77 72
23 40 72 106 46 224  205 2 3 2 0 86 88
28 42 68 136 55 259 245 2 3 2 1 82 84
28 48 62 70 131 51 252 195 2 3 2 1 92 94
29 44 75 96 46 217 195 2 3 1 1 110 102
24 39 58 125 43 226 201 2 3 2 1 106 98
30 48 67 120 64 251 190 2 3 1 1 102 98
26 39 63 113 55 231 190 2 2 2 1 98 102
31 49 70 98 45 213 192 2 3 2 0 106 108
Block Onset Time (Control Group) Regression Time Intensity of motor block
15 mins 30 mins 60 mins 120 mins 150 mins 180 mins 210 mins 240 mins 1 mins 5 mins 15 mins 30 mins 60 mins 120 mins
76 80 70 72 0 0 0 0 135 130 125 120 113 120
94 95 110 90 88 90 0 0 110 110 110 090 091 096
88 90 86 88 86 92 0 0 130 130 135 130 120 110
65 67 69 70 72 74 0 0 110 100 102 090 112 110
90 90 90 86 0 0 0 0 130 122 130 132 136 126
95 90 82 88 90 86 0 0 129 130 120 132 120 120
90 96 98 86 90 0 0 0 110 110 090 086 100 102
76 78 76 86 82 0 0 0 130 136 128 130 140 130
76 78 76 86 82 84 0 0 130 136 128 130 140 130
56 56 65 68 62 0 0 0 130 127 126 120 120 110
84 80 84 82 88 0 0 0 140 144 136 140 142 146
68 62 66 72 0 0 0 0 130 120 124 110 114 110
88 90 92 94 86 0 0 0 140 120 110 116 120 120
80 76 78 80 82 0 0 0 130 120 110 112 116 120
86 82 78 76 72 0 0 0 160 150 140 144 130 126
108 120 118 113 114 108 0 0 139 138 140 138 130 136
96 110 108 107 112 118 0 0 140 138 130 126 132 112
108 112 116 114 108 106 0 0 130 128 128 128 132 114
112 114 121 112 108 111 0 0 120 110 168 102 096 106
96 98 102 92 94 0 0 0 150 140 130 120 108 112
Intra op Hemodynamics (pulse rate per min) (Control Group) Intra op Hemodynamics (systolic BP in
150 mins 180 mins 210 mins 240 mins 1 mins 5 mins 15 mins 30 mins 60 mins 120 mins
150 
mins
180 
mins
210 
mins
240 
mins Intra OP Drugs
000 000 000 000 80 80 80 90 70 70 00 00 00 00 ---
092 100 000 000 80 80 80 50 52 54 56 70 00 00 Inj. Ephedrine-18mg/inj.midazolam 1.5mg/inj pentazocine 30mg
122 122 000 000 80 80 85 90 70 80 72 70 00 00 inj.pentazocine 30mg/inj midazolam 1mg
122 110 000 000 70 70 76 70 72 72 72 72 00 00 Inj. Ephedrine 12mg/inj pentazocine 15mg/inj.midazolam 1mg
000 000 000 000 70 70 90 90 90 92 00 00 00 00 Inj.pentazocine 15mg/inj.midazolam 1mg
130 122 000 000 80 80 70 82 80 88 84 80 00 00 inj.petazocine 15mg/inj.midazolam 1mg
112 000 000 000 80 80 60 64 70 76 82 00 00 00 Inj. Ephedrine 12mg/inj.pentazocine 30mg
122 000 000 000 80 80 80 82 90 80 84 00 00 00 inj.pentazocine 15mg/inj.midazolam 1mg
122 124 000 000 80 80 80 82 90 80 84 86 00 00 Ephedrine 6mg/inj midazolam 1mg/inj.pentazocine15mg
116 000 000 000 80 80 80 70 76 82 84 00 00 00 Inj. Atropine 0.6mg/inj.pentazocine 15mg/inj.midazolam 1mg
132 000 000 000 90 90 90 90 94 94 88 00 00 00 inj midazolam 2mg/inj.pentazocine 15mg
000 000 000 000 80 80 76 80 86 72 00 00 00 00 inj.midazolam 2mg
124 000 000 000 80 80 80 88 76 74 72 00 00 00 inj.midazolam 2mg
122 000 000 000 80 80 80 88 78 76 80 00 00 00 inj.midazolam 2mg
130 000 000 000 98 98 84 86 80 84 90 00 00 00 inj.pentazocine 15mg/inj.midazolam 1mg
130 126 000 000 96 96 90 90 80 84 80 80 00 00 ---
120 122 000 000 90 90 92 86 88 78 70 88 00 00 inj.pentazocine 15mg/inj.midazolam 1mg
126 122 000 000 90 90 94 86 88 80 78 88 00 00 inj.pentazocine15mg/inj.midazolam 1mg
110 116 000 000 86 86 76 78 70 70 76 70 00 00 Ephedrine 12mg/inj.pentazocine 15mg/inj.midazolam 1mg
120 000 000 000 90 90 88 70 70 74 78 00 00 00 Ephedrine 12mg/inj.pentazocine 30mg/inj.midazolam 1mg
Intra op Hemodynamics (diastolic BP in mmhg)n mmhg) (Control Group)
Ephedrine   (6mg) Atropine (0.6mg) pentazocine (6mg) Midazolam (1mg) Post Of Analgesia (mins)
0 0 0 0 290
3 0 5 1.5 280
0 0 5 1 315
2 0 2.5 1 330
0 0 2.5 1 335
0 0 2.5 1 310
2 0 5 0 320
0 0 2.5 1 295
1 0 2.5 1 315
0 1 2.5 1 325
0 0 2.5 2 296
0 0 0 2 311
0 0 0 2 293
0 0 0 2 350
0 0 2.5 1 278
0 0 0 0 274
0 0 2.5 1 330
0 0 2.5 1 281
2 0 2.5 1 305
2 0 2.5 1 347
intra op drugs (Control Group)
